期刊文献+

脑利钠肽对舒张性心力衰竭病人血管内皮功能和左室舒张功能的影响 被引量:7

Effects of recombinant human brain natriuretic peptide on endothelial function and left ventricular diastolic function in diastolic heart failure
原文传递
导出
摘要 目的观察重组人脑利钠肽(rhBNP)对初发舒张性心力衰竭(DHF)病人血管内皮功能和左室舒张功能的影响。方法将65例初发DHF病人随机分为对照组(30例)和rhBNP组(35例),对照组接受常规抗心力衰竭治疗,rhBNP组在常规治疗的同时加用rhBNP,首先以1.5μg·kg-1静脉冲击,然后以0.0075μg·kg-1·min-1的速度持续滴注5h,每周1次,共12wk。入选前和治疗12wk后测定各组病人的左室舒张功能指标、内皮素-1(ET-1)、一氧化氮(NO)和血管假性血友病因子(vWF)。结果rhBNP组治疗后二尖瓣口舒张早期及舒张晚期流速峰值比值(E/A)和NO较之同期对照组显著增加[(1.1±s0.4)vs(0.8±0.5),(67±13)μmol·L-1vs(49±13)μmol·L-1](P<0.05);左室等容舒张时间(IVRT)、E波减速时间(EDT)、收缩压、ET-1、vWF水平较之同期对照组明显减低[(80±6)msvs(95±6)ms,(140±21)msvs(161±28)ms,(141±23)mmHgvs(146±30)mmHg,(43±28)ng·L-1vs(56±12)ng·L-1,(110±24)%vs(149±32)%](P<0.05)。结论rhBNP对初发DHF病人具有保护血管内皮功能、改善舒张功能和降压的综合效应。 AIM To investigate the effects of recombinant human brain natriuretic peptide (rhBNP) on endothelial function and left ventricular diastolic function in patients with initialonset of diastolic heart failure (DHF). METHODS Sixty-five patients with initialonset of DHF were randomly divided into two groups. Control group (30 patients) was treated with the routine anti-heart failure therapy, while rhBNP group (35 patients) was assigned under the routine therapy plus rhBNP (1.5 μg·kg^-1 intravenous bolus followed by a 0.007 5 μg· kg^-1 ·mix-1 infusion for 5 hours, once a week for 12 weeks). Before and after 12 weeks' treatment, left ventricular diastolic function, endothelin-1 (ET-1), nitric oxide (NO) and yon willebrand factor (vWF) were measured respectively for both groups. RESULTS After treatment, E/A and serum NO in the rhBNP group were significantly higher than that in the control group ((1.1 ± s 0.4) vs (0.8 ± 0.5), (67 ±13) μmol·L^-1 vs (49± 13) μmol·L^-1), respectively (P 〈 0.05) ; isovolumicetric relaxation time (IVRT), E-wave deceleration time (EDT), systolic blood pressure, ET-1, vWF were lower than those in the control group ((80 ± 6) ms vs (95±6) ms, (140±21) msvs (161±28) ms, (141±23) mmHgvs (146±30) mmHg, (43±28) ng· L^-1 vs (56 ± 12) ng·L^-1, (110 ± 24) % vs (149 ± 32) %), respectively (P 〈 0.05). CONCLUSION rhBNP can protect endothelial function, improve left ventricular diastolic function and reduce blood pressure for initialonset DHF.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2009年第4期254-257,共4页 Chinese Journal of New Drugs and Clinical Remedies
关键词 心力衰竭 充血性 内皮 血管 药物疗法 左室舒张功能 重组入脑利钠朕 heart failure, congestive endothelium, vascular drug therapy left ventricular diastolicfunction recombinant human brain natriuretic peptide
  • 相关文献

参考文献9

  • 1GARY R, DAVIS L. Diastolic heart failure [J]. Heart Lung, 2008, 37(6): 405-416.
  • 2VILA N V, MARTINEZ-SALES V, ALMENAR L, et al. Inflammation, endothelial dysfunction and angiogenesis markers in chronic heart failure patients[J]. Int J Cardiol, 2008, 130 (2) : 276-277.
  • 3YAMAGUCHI H, YOSHIDA J, YAMAMOTO K, et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy[J]. J Am Coll Cardiol, 2004, 43(1 ) : 55-60.
  • 4YANCY CW, SALTZBERG MT, BERKOWITZ RL, et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION Ⅰ trial)[J]. Am J Cardiol, 2004, 94(5) : 595-601.
  • 5BURLEY DS, BAXTER GF. B-type natriuretic peptide at early reperfusion limits infarct size in the rat isolated heart [J]. Basic Res Cardiol, 2007, 102(6): 529-541.
  • 6PIECHOTA M, BANACH M, JACO A, et al. Natriuretic peptides in cardiovascular diseases[J]. Cell Mol Biol Lett, 2008, 13(2) : 155-181.
  • 7YTURRALDE RF, GAASCH WH. Diagnostic criteria for diastolic heart failure[J]. Prog Cardiovase Dis, 2005, 47 (5) : 314- 319.
  • 8HARGETT CW, TAPSON VF. Brain natriuretic peptide: diagnostic and therapeutic implications in pulmonary arterial hypertension[J]. Semin Respir Crit Care Med, 2005, 26 (4): 385-393.
  • 9吴小庆,孙铸兴,王强,张常莹,高运来,王如兴,王雁娟.重组脑钠肽对顽固性心衰伴肾功能不全病人血流动力学及肾功能影响[J].中国新药与临床杂志,2008,27(10):768-771. 被引量:5

二级参考文献17

  • 1毛拥军,张春华,刘松,陈祥鸿.脑钠肽与充血性心力衰竭的治疗[J].中华心血管病杂志,2004,32(9):855-857. 被引量:47
  • 2黄震华.奈西立肽——心力衰竭治疗的又一新药[J].中国新药与临床杂志,2005,24(12):981-984. 被引量:2
  • 3TAYLOR JA, CHRISTENSON RH, RAO K, et al. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures[J]. Am Heart J, 2006, 152 (6): 1071-1076.
  • 4WANG DJ, DOWLING TC, MEADOWS D, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine [J]. Circulation, 2004, 110(12): 1620-1625.
  • 5LAVILLA G, FRONZAROLI C, LAZZERI C, et al. Cardiovascular and renal effects of low dose brain natriuretic peptide infusion in man[J]. J Clin Endocrinol Metab, 1994, 78 (5): 1166-1171.
  • 6BUTLER J, EMERMAN C, PEACOCK WF, et al. The efficacy and safety of .B-type natriuretic peptide (nesiritide)in patients with renal insufficiency and acutely decompensated congestive heart failure[J]. Nephrol Dial Transplant, 2004, 19 (2): 391- 399.
  • 7BELTOWSKI J, WOJCICKA G. Regulation of renal tubular sodium transport by cardiac natriuretic peptide: two decades of research[J]. Med Sci Monit, 2002, 8(2) : RA39-RA52.
  • 8MISTRY SK, CHATTERJEE PK, WEERAKODY RP, et al. Evidence for atrial natriuretic factor induced natriuretic peptide receptor subtype switching in rat proximal tubular cells during culture[J]. Exp Nephrol, 1998, 6(2) : 104-111.
  • 9KEATING GM, GOA KL. Nesiritide: a review of its use in acute decompensated heart failure[J]. Drugs, 2003, 63( 1 ) : 47-70.
  • 10PEACOCK WF 4 th, EMERMAN CL, YOUNG J. Nesiritide in congestive heart failure associated with acute coronary syndromes: a pilot study of safety and efficacy[J]. J Card Fail, 2004, 10(2): 120-125.

共引文献4

同被引文献57

引证文献7

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部